Healthcare Industry News: uterine fibroids
News Release - August 21, 2013
Halt Medical, Inc. Announces That Brigham and Women's Faulkner Hospital is First New England Provider of the Acessa(TM) ProcedureLIVERMORE, Calif., Aug. 21, 2013 -- (Healthcare Sales & Marketing Network) -- Halt Medical, Inc. announced today that Brigham and Women's Faulkner Hospital is the first hospital in New England to treat patients with the Acessa Procedure.
The Acessa Procedure is a new minimally invasive, same-day (outpatient) therapy for fibroids of all types and sizes, in all locations within the uterine wall. It uses a technology called radiofrequency ablation. Each fibroid is destroyed by applying energy through a small needle array. The surrounding normal tissue is not affected. The destroyed tissue may then be completely reabsorbed.
Before the Acessa Procedure, treatment involved cutting through layers of healthy tissue to gain access to the fibroids, or removing the uterus completely through a hysterectomy. This new technology allows surgeons to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day, with little pain, and enjoy a rapid recovery and return to normal activity.
"We are extremely proud to be affiliated with a facility that has such a fantastic reputation and is as dedicated to women's health as we are here at Halt Medical," said Jeffrey M. Cohen, Halt Medical CEO. "The Acessa Procedure represents a breakthrough in addressing one of the biggest unmet needs in women's health. We are excited to partner with Dr. Jim Greenberg in bringing this solution to the women of New England through Brigham and Women's Faulkner Hospital."
Brigham and Women's Faulkner Hospital is a member of the Brigham and Women's family of hospitals – a recognized worldwide leader in women's healthcare.
"Any technology that gives us the ability to give women more choices for uterus-sparing treatments for fibroids is exciting," said Dr. Greenberg, who is an associate clinical professor at Harvard Medical School. "I am also thrilled that once again, Brigham and Women's Faulkner Hospital has been able to demonstrate its leadership position in minimally invasive surgery in women's health."
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.
About Brigham and Women's Faulkner Hospital
Brigham and Women's Faulkner Hospital is a 150 bed non-profit, community teaching hospital located in southwest Boston. Founded in 1900, they offer comprehensive medical, surgical and psychiatric care as well as complete emergency, ambulatory and diagnostic services. For more information, visit www.brighamandwomensfaulkner.org.
Source: Halt Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.